| Title |
Increased adherence eight months after switch from twice daily calcineurin inhibitor based treatment to once daily modified released tacrolimus in heart transplantation
|
|---|---|
| Published in |
Drug Design, Development and Therapy, October 2013
|
| DOI | 10.2147/dddt.s52820 |
| Pubmed ID | |
| Authors |
Andreas O Doesch, Susanne Mueller, Ceylan Akyol, Christian Erbel, Lutz Frankenstein, Arjang Ruhparwar, Philipp Ehlermann, Thomas J Dengler, Hugo A Katus |
| Abstract |
Modified-release tacrolimus (TAC) is a new, once-daily oral formulation of the established immunosuppressive agent TAC. This study evaluated long-term patient adherence, as well as safety and efficacy, in stable patients after heart transplantation (HTx) who switched from a conventional twice daily calcineurin inhibitor-based regimen (TAC or cyclosporine A [CsA]) to a once-daily modified-release TAC regimen. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 48 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 48 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 11 | 23% |
| Student > Bachelor | 8 | 17% |
| Student > Ph. D. Student | 4 | 8% |
| Student > Master | 3 | 6% |
| Student > Doctoral Student | 2 | 4% |
| Other | 8 | 17% |
| Unknown | 12 | 25% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 15 | 31% |
| Psychology | 5 | 10% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 8% |
| Nursing and Health Professions | 2 | 4% |
| Economics, Econometrics and Finance | 2 | 4% |
| Other | 7 | 15% |
| Unknown | 13 | 27% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 October 2013.
All research outputs
#22,756,649
of 25,371,288 outputs
Outputs from Drug Design, Development and Therapy
#1,754
of 2,268 outputs
Outputs of similar age
#194,929
of 219,838 outputs
Outputs of similar age from Drug Design, Development and Therapy
#32
of 39 outputs
Altmetric has tracked 25,371,288 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,268 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.1. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 219,838 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 39 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.